Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Investigational Drug Shows Promise in Myotonic Dystrophy Type 1

(MedPage Today) -- Investigational zeleciment basivarsen (z-basivarsen) led to functional improvement in patients with myotonic dystrophy type 1 (DM1), data from the phase I/II ACHIEVE trial suggested. The analysis evaluated whether a larger group...

Investigational Drug Shows Promise in Myotonic Dystrophy Type 1

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

Limited vaccine access hampers Kenya’s rabies prevention efforts

NAIROBI, Kenya, Oct 3 — Limited access to rabies vaccines and timely post-exposure treatment is hampering Kenya’s efforts to eliminate dog-mediated human rabies, veterinary experts have warned. Rosebella Ochango, a…

  • Limited vaccine access hampers Kenya's rabies prevention efforts.
  • Veterinary experts warn of challenges in rural, remote, and underserved areas.
  • Rabies kills about 59,000 people globally each year, mostly in Africa and Asia.

More from Saturday 3 October →